Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
出版年份 2022 全文链接
标题
Semaglutide for cardiovascular event reduction in people with overweight or obesity:
SELECT
study baseline characteristics
作者
关键词
-
出版物
Obesity
Volume 31, Issue 1, Pages 111-122
出版商
Wiley
发表日期
2022-12-11
DOI
10.1002/oby.23621
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes
- (2022) Domenica M. Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of bariatric surgery on long-term cardiovascular outcomes: a systematic review and meta-analysis of population-based cohort studies
- (2022) Borui Tang et al. Surgery for Obesity and Related Diseases
- Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
- (2022) Takashi Kadowaki et al. Lancet Diabetes & Endocrinology
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
- (2021) Thomas A. Wadden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- (2021) Melanie Davies et al. LANCET
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association
- (2021) Tiffany M. Powell-Wiley et al. CIRCULATION
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
- (2021) Domenica Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
- (2021) Dario Giugliano et al. Cardiovascular Diabetology
- SELECT (Semaglutide effects on cardiovascular outcomes in people with overweight or obesity) rationale and design
- (2020) Donna H. Ryan et al. AMERICAN HEART JOURNAL
- Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure
- (2020) Muhammad Shahzeb Khan et al. CIRCULATION
- GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
- (2020) Michael A. Nauck et al. Molecular Metabolism
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement
- (2019) Ian J Neeland et al. Lancet Diabetes & Endocrinology
- Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
- (2018) Erin A. Bohula et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors
- (2016) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial
- (2016) Lancet Diabetes & Endocrinology
- Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial
- (2010) Eric J Topol et al. LANCET
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
- (2010) W. Philip T. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0·5 could be a suitable global boundary value
- (2010) Lucy M. Browning et al. NUTRITION RESEARCH REVIEWS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started